Societal Cdmo Inc Revenue Growth Rates (SCTL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Societal Cdmo Inc   (NASDAQ: SCTL)
 

SCTL's Revenue Growth by Quarter and Year

Societal Cdmo Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SCTL Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December 27.72
3rd Quarter September 23.59
2nd Quarter June 21.80
1st Quarter March 21.53
FY 94.64

SCTLs Annual Revenue
Societal Cdmo Inc 's Revenue in the fiscal year 2023 $ 94.64 millions
Societal Cdmo Inc 's Revenue in the fiscal year 2022 $ 90.21 millions
Societal Cdmo Inc 's Revenue in the fiscal year 2021 $ 75.36 millions
Societal Cdmo Inc 's Revenue in the fiscal year 2020 $ 66.50 millions
Societal Cdmo Inc 's Revenue in the fiscal year 2019 $ 99.22 millions




SCTL Revenue fourth quarter 2023 Y/Y Growth Comment
Societal Cdmo Inc achieved in the fourth quarter 2023, above Company average Revenue increase of 14.16% year on year, to $ 27.72 millions.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 121 other companies have achieved higher Revenue growth. While Societal Cdmo Inc ' s Revenue growth of 14.16% ranks overall at the positon no. 1266 in the fourth quarter 2023.


SCTL Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December 14.16 % 8.88 % 125.03 % -43.82 %
3rd Quarter September 9.26 % 18.37 % -5.44 % -23.63 %
2nd Quarter June -5.83 % 28.47 % 16.11 % -50.35 %
1st Quarter March 1.6 % 26.13 % -22.87 % -13.12 %
FY   4.91 % 19.71 % 13.32 % -

Financial Statements
Societal Cdmo Inc 's fourth quarter 2023 Revenue $ 27.72 millions SCTL's Income Statement
Societal Cdmo Inc 's fourth quarter 2022 Revenue $ 24.28 millions Quarterly SCTL's Income Statement


SCTL Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December 17.5 % 12.46 % 22.26 % -48.63 %
3rd Quarter September 8.21 % -6.74 % 1.22 % 24.29 %
2nd Quarter June 1.25 % 9.25 % 7.26 % -28.74 %
1st Quarter March -11.33 % -4.98 % 69.53 % 23.47 %
FY (Year on Year)   4.91 % 19.71 % 13.32 % -


Back to SCTL Growth rate Comparisons >> Back to SCTL Growth rate Comparisons >>


Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #122
Healthcare Sector #291
Overall #1266

Revenue Y/Y Growth Statistics
High Average Low
124.99 % 7.81 % -50.34 %
(Sep 30 2022)   (Mar 31 2021)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #122
Healthcare Sector #291
Overall #1266
Revenue Y/Y Growth Statistics
High Average Low
124.99 % 7.81 % -50.34 %
(Sep 30 2022)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Societal Cdmo Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
69.5 % 3.19 % -48.6 %
(Mar 31 2021)  


SCTL's IV. Quarter Q/Q Revenue Comment
Societal Cdmo Inc achieved in the IV. Quarter 2023 above company average sequential Revenue jump of 17.5%, to $ 27.72 millions, from $23.59 millions in the third quarter.
SCTL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 91 other companies have achieved higher Revenue quarter on quarter growth. While Societal Cdmo Inc 's Revenue growth quarter on quarter, overall rank is 898.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #92
Healthcare Sector #212
Overall #898
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #92
Healthcare Sector #212
Overall #898
Revenue Q/Q Growth Statistics
High Average Low
69.5 % 3.19 % -48.6 %
(Mar 31 2021)  


SCTL's IV. Quarter Q/Q Revenue Comment
Societal Cdmo Inc achieved in the IV. Quarter 2023 above company average sequential Revenue jump of 17.5%, to $ 27.72 millions, from $23.59 millions in the third quarter.
SCTL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 91 other companies have achieved higher Revenue quarter on quarter growth. While Societal Cdmo Inc 's Revenue growth quarter on quarter, overall rank is 898.


Societal Cdmo Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 94.64 $ 91.20 $ 89.19 $ 90.55 $ 90.21
Y / Y Revenue Growth (TTM) 4.9 % 3.35 % 5.08 % 13.54 % 19.71 %
Year on Year Revenue Growth Overall Ranking # 806 # 223 # 567 # 736 # 1065
Seqeuential Revenue Change (TTM) 3.77 % 2.24 % -1.49 % 0.37 % 2.24 %
Seq. Revenue Growth (TTM) Overall Ranking # 2463 # 1857 # 1681 # 1951 # 765


Cumulative Revenue growth Comment
Although Societal Cdmo Inc 's Annual Revenue growth year on year were below company's average 6.07% , Revenue announced in the Dec 31 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 4.9% year on year, from 3.35% in Sep 30 2023.

In the Healthcare sector 189 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 223 to 806.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 150
Healthcare Sector # 190
Overall # 806

Revenue TTM Y/Y Growth Statistics
High Average Low
40.13 %
 6.07 %
-35.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 150
Sector # 401
S&P 500 # 2463
Cumulative Revenue growth Comment
Although Societal Cdmo Inc 's Annual Revenue growth year on year were below company's average 6.07% , Revenue announced in the Dec 31 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 4.9% year on year, from 3.35% in Sep 30 2023.

In the Healthcare sector 189 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 223 to 806.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 150
Healthcare Sector # 190
Overall # 806

Revenue TTM Y/Y Growth Statistics
High Average Low
40.13 %
6.07 %
-35.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 150
Sector # 401
S&P 500 # 2463




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SCTL's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Strata Critical Medical Inc 24.50%$ 24.500 millions
Alkermes Plc 23.89%$ 23.895 millions
Aquestive Therapeutics Inc 23.63%$ 23.629 millions
Sotera Health Company23.61%$ 23.612 millions
Xoma Royalty Corporation23.35%$ 23.351 millions
Vericel Corporation23.35%$ 23.346 millions
Ultragenyx Pharmaceutical Inc 23.27%$ 23.265 millions
Inari Medical Inc 22.95%$ 22.949 millions
Surmodics Inc 22.54%$ 22.536 millions
Lifestance Health Group Inc 22.34%$ 22.342 millions
Veracyte Inc 22.29%$ 22.295 millions
Guardant Health Inc 22.19%$ 22.195 millions
Cytek Biosciences Inc 22.06%$ 22.058 millions
Cardiff Oncology Inc 21.87%$ 21.875 millions
Apyx Medical Corp21.80%$ 21.798 millions
Alpha Pro Tech Ltd 21.78%$ 21.783 millions
Protalix Biotherapeutics inc 21.69%$ 21.690 millions
Fortress Biotech Inc 21.59%$ 21.592 millions
Si bone inc 21.28%$ 21.278 millions
Olink Holding Ab publ 21.18%$ 21.175 millions
Ensign Group Inc21.10%$ 21.104 millions
Atricure Inc 21.03%$ 21.033 millions
Whitehawk Therapeutics Inc 21.03%$ 21.025 millions
Privia Health Group Inc 20.97%$ 20.966 millions
Biotricity Inc 20.89%$ 20.893 millions
Acorda Therapeutics Inc 20.70%$ 20.702 millions
Bruker Corporation20.62%$ 20.624 millions
Biomarin Pharmaceutical Inc20.22%$ 20.216 millions
The Oncology Institute Inc 20.11%$ 20.111 millions
Theravance Biopharma inc 19.91%$ 19.906 millions


About Societal Cdmo Inc Revenue Growth Rates (SCTL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Societal Cdmo Inc (CIK 1588972).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-24-035480
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Societal Cdmo Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.